Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Beginning Cash Balance: 2009-2025

Historic Beginning Cash Balance for China Pharma Holdings (CPHI) over the last 17 years, with Sep 2025 value amounting to $657,407.

  • China Pharma Holdings' Beginning Cash Balance fell 11.08% to $657,407 in Q3 2025 from the same period last year, while for Sep 2025 it was $751,066, marking a year-over-year decrease of 45.17%. This contributed to the annual value of $1.4 million for FY2024, which is 29.86% down from last year.
  • Latest data reveals that China Pharma Holdings reported Beginning Cash Balance of $657,407 as of Q3 2025, which was up 59.30% from $412,688 recorded in Q2 2025.
  • In the past 5 years, China Pharma Holdings' Beginning Cash Balance registered a high of $4.9 million during Q1 2022, and its lowest value of $412,688 during Q2 2025.
  • Over the past 3 years, China Pharma Holdings' median Beginning Cash Balance value was $838,881 (recorded in 2024), while the average stood at $989,675.
  • In the last 5 years, China Pharma Holdings' Beginning Cash Balance skyrocketed by 540.86% in 2022 and then tumbled by 68.59% in 2023.
  • Over the past 5 years, China Pharma Holdings' Beginning Cash Balance (Quarterly) stood at $458,831 in 2021, then spiked by 354.70% to $2.1 million in 2022, then crashed by 34.34% to $1.4 million in 2023, then plummeted by 47.54% to $718,691 in 2024, then fell by 11.08% to $657,407 in 2025.
  • Its last three reported values are $657,407 in Q3 2025, $412,688 for Q2 2025, and $626,879 during Q1 2025.